AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39419061 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment following neoadjuvant treatment.
Number of subjects: 46
Study 39419177 — intervention group
Group type: EXPERIMENTAL
Intervention: UM171-expanded single cord blood unit transplantation
Number of subjects: 0
Study 39419177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39419348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg for TOF count ≥1 and 4 mg/kg for TOF count = 0)
Number of subjects: 51
Study 39419367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis identifying five distinct phenotypes based on somatosensory and psychosocial characteristics pre- and post-surgery.
Number of subjects: 184
Study 39419367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher psychosocial distress and lower QoL correlated with elevated pain intensity one year post-surgery.
Number of subjects: 184
Study 39419367 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale for pain intensity evaluation one year post-surgery.
Number of subjects: 184
Study 39419473 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal depressive symptoms
Number of subjects: 739
Study 39419473 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficits in cold EF
Number of subjects: 739
Study 39419473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot EF
Number of subjects: 739
Study 39419550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy anxiety
Number of subjects: 0
Study 39419550 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39419615 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered guided self-help tinnitus treatment based on ACT combined with tailored sound therapy
Number of subjects: 164
Study 39419615 — intervention group
Group type: COMPARATOR
Intervention: Tailored sound therapy alone
Number of subjects: 164
Study 39419729 — intervention group
Group type: EXPERIMENTAL
Intervention: TGD-informed e-health intervention for 4 months
Number of subjects: 174
Study 39419729 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 174
Study 39419729 — intervention group
Group type: EXPERIMENTAL
Intervention: TGD-informed e-health intervention
Number of subjects: 174
Study 39420060 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET/CT
Number of subjects: 102
Study 39420060 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-MDP planar bone scan plus CT
Number of subjects: 102
Study 39420169 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (live-attenuated tetravalent dengue vaccine)
Number of subjects: 200
Study 39420169 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 200
Study 39420312 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component educational hand hygiene intervention (training in hand-washing and supply of MONO-RUB)
Number of subjects: 440
Study 39420312 — intervention group
Group type: COMPARATOR
Intervention: Standard harm reduction services only (control group)
Number of subjects: 440
Study 39420338 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF/G
Number of subjects: 106
Study 39420338 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF
Number of subjects: 106
Study 39420338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 39420379 — intervention group
Group type: EXPERIMENTAL
Intervention: TARANG intervention (4 month duration, 4 sessions for husbands)
Number of subjects: 41
Study 39420379 — intervention group
Group type: EXPERIMENTAL
Intervention: TARANG intervention
Number of subjects: 41
Study 39420468 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor-neprilysin inhibitor (ARNI)
Number of subjects: 26966
Study 39420468 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor-neprilysin inhibitor (ARNI) with PDC ≥ 80%
Number of subjects: 26966
Study 39420468 — intervention group
Group type: COMPARATOR
Intervention: Traditional RAS blockade
Number of subjects: 26966
Study 39420468 — intervention group
Group type: COMPARATOR
Intervention: Traditional RAS blockade with PDC < 80%
Number of subjects: 26966
Study 39420528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie, high-protein diet from animal sources (HPA diet)
Number of subjects: 117
Study 39420528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie, high-protein diet from plant sources (HPP diet)
Number of subjects: 117
Study 39420528 — intervention group
Group type: COMPARATOR
Intervention: Both diets (HPA and HPP)
Number of subjects: 117
Study 39420566 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored financial well-being intervention
Number of subjects: 0
Study 39420566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39420668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer education
Number of subjects: 105
Study 39420701 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic THA
Number of subjects: 138
Study 39420701 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments (Control)
Number of subjects: 138
Study 39420894 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide modified release
Number of subjects: 10
Study 39420894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 39421268 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated overdose prevention and naloxone educational video (6-minute video)
Number of subjects: 1004
Study 39421268 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004
Study 39421431 — intervention group
Group type: EXPERIMENTAL
Intervention: difelikefalin
Number of subjects: 0
Study 39421431 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 39421449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 0
Study 39421449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39421567 — intervention group
Group type: EXPERIMENTAL
Intervention: MY-Skills intervention (yoga and self-management education), offered twice a week for eight weeks, each session lasting two hours.
Number of subjects: 13
Study 39421567 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 13
Study 39421612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesfytol NG (1,000 mg Amla fruit and 50 mg Olive fruit standardized extracts)
Number of subjects: 191
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of plasma Gal-3
Number of subjects: 175
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine epidermal growth factor
Number of subjects: 175
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal-3
Number of subjects: 175
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor
Number of subjects: 175
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine biomarkers of kidney tubule injury
Number of subjects: 175
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: History of chronic kidney disease
Number of subjects: 175
Study 39421939 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite outcome
Number of subjects: 175
Study 39421941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 527
Study 39421941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 39421943 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 703
Study 39421943 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 703
Study 39422068 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-percentage-to-albumin ratio (NPAR)
Number of subjects: 240
Study 39422068 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic immune-inflammation index (SII)
Number of subjects: 240
Study 39422068 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response index (SIRI)
Number of subjects: 240
Study 39422068 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model (Random Forest algorithm)
Number of subjects: 240
Study 39422200 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin ratio in TTS patients
Number of subjects: 108
Study 39422200 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin ratio
Number of subjects: 108
Study 39422200 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin ratio at a cut-off point of 0.12
Number of subjects: 108
Study 39422261 — intervention group
Group type: EXPERIMENTAL
Intervention: CV0501 12 μg dose
Number of subjects: 180
Study 39422261 — intervention group
Group type: EXPERIMENTAL
Intervention: CV0501 3 or 6 μg dose
Number of subjects: 180
Study 39422261 — intervention group
Group type: EXPERIMENTAL
Intervention: CV0501
Number of subjects: 180
Study 39422598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fianlimab + cemiplimab (1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks)
Number of subjects: 78
Study 39422598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fianlimab monotherapy (exact dosage not specified)
Number of subjects: 78
Study 39422598 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from fianlimab monotherapy to combination therapy
Number of subjects: 78
Study 39422598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fianlimab pharmacokinetics
Number of subjects: 78
Study 39422598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fianlimab 1,600 mg Q3W (20 mg/kg in an 80-kg individual)
Number of subjects: 78
Study 39422604 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v (10 mg, QW/Q2W) in combination with cetuximab (500 mg/m2, Q2W)
Number of subjects: 58
Study 39422697 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-targeting TGF-β and PDL1 pathways
Number of subjects: 48
Study 39422697 — intervention group
Group type: COMPARATOR
Intervention: C1Q+ macrophage infiltrates
Number of subjects: 48
Study 39422741 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m2 administered as a single dose after tumor removal.
Number of subjects: 7
Study 39422741 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 7
Study 39422764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus low-dose bevacizumab
Number of subjects: 32
Study 39422837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine for 2 years
Number of subjects: 97
Study 39422837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% loading dose for 6 months followed by 0.01% for 18 months
Number of subjects: 97
Study 39422837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 39422853 — intervention group
Group type: EXPERIMENTAL
Intervention: V0034CR (glycerol 15% and paraffin 10%)
Number of subjects: 235
Study 39422853 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 235
Study 39422853 — intervention group
Group type: EXPERIMENTAL
Intervention: V0034CR
Number of subjects: 235
Study 39422889 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention (6-minute explainer video)
Number of subjects: 1971
Study 39422889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational video)
Number of subjects: 1971
Study 39422911 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour PAP
Number of subjects: 193
Study 39422911 — intervention group
Group type: COMPARATOR
Intervention: Extended PAP
Number of subjects: 193
Study 39422912 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 14 days
Number of subjects: 1250
Study 39422912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study 39422912 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 1250
Study 39422935 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 100
Study 39422935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 39422941 — intervention group
Group type: EXPERIMENTAL
Intervention: Varoglutamstat
Number of subjects: 0
Study 39422960 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene delivery of brain derived neurotrophic factor (BDNF)
Number of subjects: 0
Study 39422960 — intervention group
Group type: COMPARATOR
Intervention: Nerve growth factor (NGF) gene therapy
Number of subjects: 0
Study 39422992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mission Reconnect (MR) intervention
Number of subjects: 364
Study 39422992 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 364
Study 39422992 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative outcomes from MR intervention
Number of subjects: 364
Study 39423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 0
Study 39423023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Kidney Function Decline
Number of subjects: 0
Study 39423043 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Yoga and Psychological Intervention
Number of subjects: 0
Study 39423145 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg
Number of subjects: 203
Study 39423145 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg
Number of subjects: 203
Study 39423145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 39423154 — intervention group
Group type: EXPERIMENTAL
Intervention: Altis single-incision sling
Number of subjects: 355
Study 39423154 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (full-length slings)
Number of subjects: 355
Study 39423312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 72
Study 39423312 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 72
Study 39423355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) plus Bevacizumab (15 mg/kg)
Number of subjects: 162
Study 39423355 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab plus placebo
Number of subjects: 162
Study 39423450 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Japan (n=11)
Number of subjects: 40
Study 39423450 — intervention group
Group type: COMPARATOR
Intervention: Solvent (placebo) (n=13)
Number of subjects: 40
Study 39423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 167
Study 39423758 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA and glycine together
Number of subjects: 167
Study 39423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine alone
Number of subjects: 167
Study 39423758 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 167
Study 39423758 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 167
Study 39423759 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based rehabilitation
Number of subjects: 187
Study 39423759 — intervention group
Group type: COMPARATOR
Intervention: Post-COVID-19 Syndrome patients
Number of subjects: 187
Study 39423767 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Measures in Switzerland
Number of subjects: 1875
Study 39423767 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Measures in Austria
Number of subjects: 1875
Study 39423767 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorganisational changes due to COVID-19
Number of subjects: 1875
Study 39423874 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1676
Study 39423874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676
Study 39423991 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert during visits
Number of subjects: 180
Study 39423991 — intervention group
Group type: EXPERIMENTAL
Intervention: Message between visits
Number of subjects: 180
Study 39423991 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 39423993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone in addition to usual care
Number of subjects: 3000
Study 39423993 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3000
Study 39424003 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided choledochoduodenostomy (EUS-CDS) with lumen-apposing metal stent (LAMS)
Number of subjects: 27
Study 39424003 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of fully covered self-expandable metal stent (FCSEMS) through the LAMS
Number of subjects: 27
Study 39424003 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-CDS with FCSEMS
Number of subjects: 27
Study 39424003 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-CDS
Number of subjects: 27
Study 39424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare resection in clopidogrel users
Number of subjects: 263
Study 39424007 — intervention group
Group type: COMPARATOR
Intervention: Cold snare resection in aspirin users
Number of subjects: 263
Study 39424007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare resection
Number of subjects: 263
Study 39424070 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-protein blend
Number of subjects: 29
Study 39424070 — intervention group
Group type: COMPARATOR
Intervention: Milk protein
Number of subjects: 29
Study 39424070 — intervention group
Group type: COMPARATOR
Intervention: No added protein
Number of subjects: 29
Study 39424070 — intervention group
Group type: EXPERIMENTAL
Intervention: All meal compositions
Number of subjects: 29
Study 39424112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs) in low neighborhood deprivation
Number of subjects: 183
Study 39424112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs) in average neighborhood deprivation
Number of subjects: 183
Study 39424112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs) in high neighborhood deprivation
Number of subjects: 183
Study 39424189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks for 52 weeks (QUEST)
Number of subjects: 1584
Study 39424189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 96 weeks (TRAVERSE)
Number of subjects: 1584
Study 39424189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab/dupilumab group
Number of subjects: 1584
Study 39424189 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 52 weeks (QUEST)
Number of subjects: 1584
Study 39424189 — intervention group
Group type: COMPARATOR
Intervention: Placebo/dupilumab group
Number of subjects: 1584
Study 39424304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve (BAV)
Number of subjects: 310
Study 39424304 — intervention group
Group type: COMPARATOR
Intervention: Tricuspid aortic valve (TAV)
Number of subjects: 310
Study 39424304 — intervention group
Group type: EXPERIMENTAL
Intervention: BAV phenotype
Number of subjects: 310
Study 39424304 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher low-density lipoprotein (LDL) levels
Number of subjects: 310
Study 39424377 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Connections (FC)
Number of subjects: 48
Study 39424377 — intervention group
Group type: COMPARATOR
Intervention: Waitlist standard-care group
Number of subjects: 48
Study 39424380 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic active case finding using the SPLASH technique
Number of subjects: 1500
Study 39424388 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge experiences and transition process from hospital to community
Number of subjects: 182
Study 39424402 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine neurologist assessment
Number of subjects: 270
Study 39424402 — intervention group
Group type: COMPARATOR
Intervention: Onboard assessment
Number of subjects: 270
Study 39424467 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibiotics
Number of subjects: 87
Study 39424467 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotics
Number of subjects: 87
Study 39424513 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily plus bevacizumab 15 mg/kg every 3 weeks
Number of subjects: 0
Study 39424513 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib monotherapy 80 mg once daily
Number of subjects: 0
Study 39424558 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 1777
Study 39424558 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 1777
Study 39424559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 336
Study 39424559 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 336
Study 39424559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Therapy (CBT + Modafinil)
Number of subjects: 336
Study 39424560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 30 mg (15 mg twice daily)
Number of subjects: 120
Study 39424560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 60 mg (30 mg twice daily)
Number of subjects: 120
Study 39424560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 39424598 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg once-weekly subcutaneous semaglutide (GLP-1 RA)
Number of subjects: 792
Study 39424598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 39424626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognivue Clarity
Number of subjects: 887
Study 39424742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2 mg/day
Number of subjects: 247
Study 39424768 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after abnormal screening results
Number of subjects: 241
Study 39424775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine (2-20 μg/kg/h)
Number of subjects: 292
Study 39424775 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (1.5-12 μg/kg/h)
Number of subjects: 292
Study 39425012 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based breathing and chest mobility exercise 3x/week for 12 weeks
Number of subjects: 46